Yep "reactionary" It was made crystal clear during AGM preso when ASF has each director to justify their fees. John Gaffney as director and Chair of REM Committee only decided to seek to benchmark REM once he realised the AGM resolutions count from proxy online voting was ugly. Then proceed to give us the typical waffle "good governance". Actual good governance from the REM committee should have started 4 years ago.
Other telling bits from the AGM was Amos's response to the ASF's question on whether he intends to purchase a single share in PAR:....."umm....I have thought about acquiring shares"
I feel for PR as I feel he is quite capable but compensating for others in his team. But yes as the CEO it was his responsibility in the first instance.
New CEO needed as this team is realistically not capable of coordinating the most complex milestones ahead...... Harmonized global clinical trials
research reports and media, page-2490
-
- There are more pages in this discussion • 1,915 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 337 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 138166 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |